[Research progress of PCSK9 inhibitor pleiotropy].

Feng, S Q; Wang, Y F; Chen, P P; Zhang, Z Y; Zhang, S Y

Feng, S Q; Wang, Y F; Chen, P P; Zhang, Z Y; Zhang, S Y.

Afiliação

Feng SQ; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Wang YF; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Chen PP; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhang ZY; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.
Zhang SY; Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

Zhonghua Xin Xue Guan Bing Za Zhi ; 50(3): 313-318, 2022 Mar 24.

Article em Zh | MEDLINE | ID: mdl-35340155

Assuntos

Hiperlipoproteinemia Tipo II; Pró-Proteína Convertase 9; Antivirais; LDL-Colesterol; Humanos; Pró-Proteína Convertase 9/genética

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pró-Proteína Convertase 9 / Hiperlipoproteinemia Tipo II Limite: Humans Idioma: Zh Revista: Zhonghua Xin Xue Guan Bing Za Zhi Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google